Literature DB >> 8081871

Suppression of mouse melanoma metastasis by EA-1, a monoclonal antibody specific for alpha 6 integrins.

P Ruiz1, D Dunon, A Sonnenberg, B A Imhof.   

Abstract

The rat monoclonal antibody (mAb) termed EA-1 was originally selected for its capacity to block the adhesion of T lymphocyte progenitors to mouse thymic endothelium. Here we show that the mAb EA-1 recognizes the alpha 6 chain of alpha 6 beta 1 and alpha 6 beta 4 integrins. Both molecules are present at a high level on the luminal and basolateral side of vascular endothelium and alpha 6 beta 1 integrin is expressed on the highly metastatic cell lines B16/129 (melanoma) and KLN-205 (carcinoma). These lung specific tumors bind preferentially to lung frozen sections, and EA-1 blocked this interaction in vitro. Moreover, mAb EA-1 inhibited experimental metastasis to the lung of B16/129 cells injected intravenously. Metastasis in vivo was blocked when the antibody was injected into mice before or simultaneously with the melanoma cells, as well as when melanoma cells were precoated with EA-1 before injection. We suggest that alpha 6 integrins play a dual role in the metastatic process, mediating the adhesion of tumor cells to the luminal surface of the endothelium and the adhesion to laminin in the subendothelial extracellular matrix during extravasation. Despite the fact that alpha 6 integrins are laminin receptors, EA-1 did not interfere with melanoma cell binding to laminin fragments. Our antibody EA-1 may therefore recognize a binding domain on alpha 6 integrins of a novel ligand involved in cell-cell interaction.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8081871

Source DB:  PubMed          Journal:  Cell Adhes Commun        ISSN: 1023-7046


  16 in total

1.  A monoclonal antibody against an activation epitope on mouse integrin chain beta 1 blocks adhesion of lymphocytes to the endothelial integrin alpha 6 beta 1.

Authors:  M Lenter; H Uhlig; A Hamann; P Jenö; B Imhof; D Vestweber
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-01       Impact factor: 11.205

2.  Increased levels of alpha6 integrins are associated with the metastatic phenotype of human breast cancer cells.

Authors:  R Mukhopadhyay; R L Theriault; J E Price
Journal:  Clin Exp Metastasis       Date:  1999-06       Impact factor: 5.150

3.  Differential expression of extracellular matrix molecules and the alpha 6-integrins in the normal and neoplastic prostate.

Authors:  J D Knox; A E Cress; V Clark; L Manriquez; K S Affinito; B L Dalkin; R B Nagle
Journal:  Am J Pathol       Date:  1994-07       Impact factor: 4.307

4.  The use of a combinatorial library method to isolate human tumor cell adhesion peptides.

Authors:  M E Pennington; K S Lam; A E Cress
Journal:  Mol Divers       Date:  1996-10       Impact factor: 2.943

5.  Adhesion of renal carcinoma cells to endothelial cells depends on PKCmu.

Authors:  Walburgis Brenner; Silke Beitz; Elke Schneider; Frank Benzing; Ronald E Unger; Frederik C Roos; Joachim W Thüroff; Christian Hampel
Journal:  BMC Cancer       Date:  2010-05-06       Impact factor: 4.430

6.  Integrin alpha 6A beta 1 induces CD81-dependent cell motility without engaging the extracellular matrix migration substrate.

Authors:  S Z Domanico; A J Pelletier; W L Havran; V Quaranta
Journal:  Mol Biol Cell       Date:  1997-11       Impact factor: 4.138

Review 7.  The Cohesive Metastasis Phenotype in Human Prostate Cancer.

Authors:  William L Harryman; James P Hinton; Cynthia P Rubenstein; Parminder Singh; Raymond B Nagle; Sarah J Parker; Beatrice S Knudsen; Anne E Cress
Journal:  Biochim Biophys Acta       Date:  2016-09-24

8.  Alpha 6 integrin distribution in human embryonic and adult tissues.

Authors:  H J Terpe; H Stark; P Ruiz; B A Imhof
Journal:  Histochemistry       Date:  1994-01

Review 9.  Fibronectin and integrins in invasion and metastasis.

Authors:  S K Akiyama; K Olden; K M Yamada
Journal:  Cancer Metastasis Rev       Date:  1995-09       Impact factor: 9.264

Review 10.  Laminin-binding integrins and their tetraspanin partners as potential antimetastatic targets.

Authors:  Christopher S Stipp
Journal:  Expert Rev Mol Med       Date:  2010-01-18       Impact factor: 5.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.